We are live on ! Find out more
Ensign Peak Advisors

Ensign Peak Advisors Portfolio holdings

AUM $53.7B
1-Year Est. Return 29.47%
This Fund
S&P 500
This Quarter Est. Return
-2.36%
1 Year Est. Return
+29.47%
3 Year Est. Return
+102.45%
5 Year Est. Return
+139.11%
10 Year Est. Return
AUM
$46.8B
AUM Growth
-$2.48B
Cap. Flow
-$831M
Cap. Flow %
-1.77%
Top 10 Hldgs %
28.11%
Holding
1,786
New
25
Increased
394
Reduced
504
Closed
30

Top Buys

Rank Stock Value
1
CCI icon
Crown Castle
CCI
+$130M
2
AMGN icon
Amgen
AMGN
+$96.1M
3
PGR icon
Progressive
PGR
+$94.9M
4
ABBV icon
AbbVie
ABBV
+$77.1M
5
KVUE icon
Kenvue
KVUE
+$75.6M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$148M
2
JNJ icon
Johnson & Johnson
JNJ
+$147M
3
LYB icon
LyondellBasell Industries
LYB
+$108M
4
DG icon
Dollar General
DG
+$91.2M
5
XOM icon
ExxonMobil
XOM
+$87.6M

Sector Composition

Rank Sector Weight
1 Technology 24.48%
2 Healthcare 17.42%
3 Financials 12.53%
4 Consumer Discretionary 9.71%
5 Communication Services 7.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EHC icon
801
Encompass Health
EHC
$11.3B
$2.23M ﹤0.01%
33,142
-2,520
-7% -$173K
CFR icon
802
Cullen/Frost Bankers
CFR
$10.5B
$2.22M ﹤0.01%
24,363
+5,344
+28% +$542K
GTLS
803
DELISTED
Chart Industries
GTLS
$2.21M ﹤0.01%
13,070
THC icon
804
Tenet Healthcare
THC
$22.2B
$2.2M ﹤0.01%
33,433
EQR icon
805
Equity Residential
EQR
$25.8B
$2.19M ﹤0.01%
37,348
-9,641
-21% -$623K
FTS icon
806
Fortis
FTS
$29.3B
$2.19M ﹤0.01%
57,351
+9,100
+19% +$372K
SWAV
807
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$2.19M ﹤0.01%
10,980
-505
-4% -$119K
RGLD icon
808
Royal Gold
RGLD
$16.6B
$2.18M ﹤0.01%
20,513
JLL icon
809
Jones Lang LaSalle
JLL
$15.8B
$2.17M ﹤0.01%
15,380
+1,515
+11% +$247K
OLED icon
810
Universal Display
OLED
$3.75B
$2.17M ﹤0.01%
13,820
WWD icon
811
Woodward
WWD
$23B
$2.17M ﹤0.01%
17,429
MUR icon
812
Murphy Oil
MUR
$5.55B
$2.16M ﹤0.01%
47,525
PRI icon
813
Primerica
PRI
$10.1B
$2.15M ﹤0.01%
11,096
NTR icon
814
Nutrien
NTR
$33.9B
$2.15M ﹤0.01%
34,639
+100
+0.3% +$6.33K
RMBS icon
815
Rambus
RMBS
$8.95B
$2.15M ﹤0.01%
38,502
-16,105
-29% -$914K
CIEN icon
816
Ciena
CIEN
$46.8B
$2.14M ﹤0.01%
45,274
AR icon
817
Antero Resources
AR
$10.9B
$2.13M ﹤0.01%
83,980
-8,745
-9% -$226K
PII icon
818
Polaris
PII
$3.83B
$2.12M ﹤0.01%
20,391
+2,185
+12% +$260K
SLAB icon
819
Silicon Laboratories
SLAB
$7.14B
$2.12M ﹤0.01%
18,275
+5,561
+44% +$768K
NMRA icon
820
Neumora Therapeutics
NMRA
$306M
$2.12M ﹤0.01%
+150,000
New +$1.87M
MEDP icon
821
Medpace
MEDP
$16.3B
$2.12M ﹤0.01%
8,735
+265
+3% +$67.8K
GNTX icon
822
Gentex
GNTX
$5.1B
$2.11M ﹤0.01%
64,911
-17,215
-21% -$552K
AFG icon
823
American Financial Group
AFG
$11.9B
$2.11M ﹤0.01%
18,871
KRG icon
824
Kite Realty
KRG
$5.86B
$2.1M ﹤0.01%
98,069
+16,690
+21% +$378K
IONS icon
825
Ionis Pharmaceuticals
IONS
$8.93B
$2.1M ﹤0.01%
46,310

Similar funds

Ensign Peak Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Ensign Peak Advisors held 1,786 positions worth $46.8B, down 5% from $49.3B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Trading was light in Q3 2023: portfolio turnover was 3.1%. Ensign Peak Advisors opened 25 new positions and exited 30, leaving the 1,786-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Healthcare and Financials.

  • Ensign Peak Advisors's largest Q3 2023 buy was Invesco QQQ Trust: 160,000 shares worth $57.3M.
  • Ensign Peak Advisors added most to Crown Castle in Q3 2023, an estimated $130M increase.
  • Ensign Peak Advisors's biggest Q3 2023 reduction was Eli Lilly, cutting an estimated $148M.
  • Ensign Peak Advisors fully exited RB Global in Q3 2023, selling an estimated $26.5M.
  • Ensign Peak Advisors's ten largest holdings make up 28% of its $46.8B portfolio in Q3 2023.
  • Ensign Peak Advisors opened 25 new positions and closed 30 in Q3 2023.
  • Ensign Peak Advisors's portfolio value fell 5% quarter-over-quarter to $46.8B.

Based on Ensign Peak Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.